المؤلفون: R. Karabut Yu., A. Vazhenin V., E. Mozerova Y., T. Sharabura M., M. Sarycheva M., A. Guz O., A. Zakharov S., Р. Карабут Ю., А. Важенин В., Е. Мозерова Я., Т. Шарабура М., М. Сарычева М., А. Гузь О., А. Захаров С.

المصدر: Head and Neck Tumors (HNT); Том 10, № 1 (2020); 20-28 ; Опухоли головы и шеи; Том 10, № 1 (2020); 20-28 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2020-10-1

مصطلحات موضوعية: recurrence of squamous cell cancer of head and neck, re-irradiation, chemotherapy, surgery, overall survival, рецидив плоскоклеточного рака головы и шеи, повторное облучение, химиотерапия, хирургическое лечение, выживаемость

وصف الملف: application/pdf

العلاقة: https://ogsh.abvpress.ru/jour/article/view/472/409Test; Chang J.H., Wu C.C., Yuan K.S.P. et al. Locoregionally recurrent head and neck squamous cell carcinoma: incidence, survival, prognostic factors, and treatment outcomes. Oncotarget 2017;8(33): 55600–12. DOI:10.18632/oncotarget.16340.; Banaszewski J., Pabiszczak M., Balcerowiak A. et al. Primary surgical treatment versus salvage surgery: results of free flap reconstruction performed in 100 patients with oropharyngeal cancer. Surg Oncol 2019;28:174–9. DOI:10.1016/j.suronc.2018.12.005.; Argiris A., Harrington K.J., Tahara M. et al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front Oncol 2017;7:72. DOI:10.3389/fonc.2017.00072.; Dornoff N., Weiß C., Rödel F et al. Reirradiation with cetuximab or cisplatinbased chemotherapy for recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol 2015;191(8):656–64. DOI:10.1007/s00066-015-0854-y.; Surmeli Z.G., Ozveren A., Arslan C. et al. Biweekly cetuximab in combination with platinum and 5-fluorouracil in metastatic head and neck carcinoma. Indian J cancer 2019;56(1):4–8. DOI:10.4103/ijc.IJC_355_18.; Muratori L., La Salvia A., Gorzegno G. et al. Long-term disease control in a metastatic squamous cell carcinoma of the oral cavity treated with maintenance metronomic capecitabine. J Oncol Pharm Pract 2019;2020:26(1):240–3. DOI:10.1177/1078155219845433.; Von der Grün J., Köhn J., Loutfi-Krauss B. et al. Second infield re-irradiation with a resulting cumulative equivalent dose (EQD2max) of >180 Gy for patients with recurrent head and neck cancer. Head Neck 2019;41(4):E48–54. DOI:10.1002/hed.25428.; Kasperts N., Slotman B.J., Leemans C.R. et al. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer 2006;106(7): 1536–47. DOI:10.1002/cncr.21768.; Pignon J.P., le Maître A., Maillard E. et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(1):4–14. DOI:10.1016/j.radonc.2009.04.014.; Corvò R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007;85(1):156–70. DOI:10.1016/j.radonc.2007.04.002.; Лавникова Г.А., Гош Т.Е., Талалаева А.В. Гистологический метод; количественной оценки степени лучевого повреждения опухоли. Медицинская радиология 1978;23(3):6–9. [Lavnikova G.A., Gosh T.E., Talalaeva A.V. Histological method of quantitative assessment of the degree of tumor radiation injury. Meditsinskaya radiologiya = Medical Radiology 1978;23(3):6–9. (In Russ.)].; Лавникова Г.А. Гистологический метод количественной оценки терапевтического повреждения опухоли. М., 1979. 13 с. [Lavnikova G.A. Histological method for the quantitative evaluation of the therapeutic lesion of tumor. Moscow, 1979. 13 p. (In Russ.)].; Steven K.R. Jr, Btitsch A., Moss W.T. et al. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1994;29(4):687–98. DOI:10.1016/0360-3016(94)90555-x.; Tanvetyanon T., Padhya T., McCaffrey J. et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol 2009;27(12):1983–91. DOI:10.1200/JCO.2008.20.0691.; Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published date: May 28, 2009. Available at: https://evs.nci.nih.gov/ftp1Test/ CTCAE/CTCAE_4.03/ Archive/CTCAE_4.0_2009-05-29_ QuickReference_8.5x11.pdf.; RTOG/EORTC Late Radiation Morbidity Scoring Schema. Available at: https:// www.rtog.org/researchassociates/ adverseeventreporting/rtogeortclateradiati onmorbidityscoringschema.aspx. 18. Fisher M.D., Fernandes A.W., Olufade T.O. et al. Effectiveness outcomes in patients with recurrent or refractory head and neck cancers: retrospective analysis of data from a community oncology database. Clin Ther 2018;40(9):1522–37. DOI:10.1016/j.clinthera.2018.07.016.; Задеренко И.А., Алиева С.Б., Дробышев А.Ю., Азизян Р.И. Рецидивы рака слизистой оболочки полости рта и ротоглотки: клиника, диагностика, лечение. Клиницист 2013;(1):48–54. [Zaderenko I.A., Aliyeva S.B., Drobyshev A.Yu., Azizyan R.I. Recurrent oral and oropharyngeal cancer: clinical picture, diagnosis, and treatment. Klinitsist = The Clinician 2013;(1):48–54. (In Russ.)].; Forastiere A.A., Metch B., Schuller D.E. et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10(8):1245–51. DOI:10.1200/JCO.1992.10.8.1245.; https://ogsh.abvpress.ru/jour/article/view/472Test

الإتاحة: https://doi.org/10.17650/2222-1468-2020-10-1-20-28Test
https://doi.org/10.17650/2222-1468-2020-10-1Test
https://doi.org/10.18632/oncotarget.16340Test
https://doi.org/10.1016/j.suronc.2018.12.005Test
https://doi.org/10.3389/fonc.2017.00072Test
https://doi.org/10.1007/s00066-015-0854-yTest
https://doi.org/10.4103/ijc.IJC_355_18Test
https://doi.org/10.1177/1078155219845433Test
https://doi.org/10.1002/hed.25428Test
https://doi.org/10.1002/cncr.21768Test

المؤلفون: A. Guz O., D. Fatkullin M., A. Garev V., A. Zakharov S., M. Sokolova I., A. Alekseeva P., А. Гузь О., Д. Фаткуллин М., А. Гарев В., А. Захаров С., М. Соколова И., А. Алексеева П.

المصدر: Head and Neck Tumors (HNT); Том 10, № 2 (2020); 54-60 ; Опухоли головы и шеи; Том 10, № 2 (2020); 54-60 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2020-10-2

مصطلحات موضوعية: head and neck tumors, antibiotic prophylaxis, surgical wound infection, clean wounds, clean-contaminated wounds, lymphadenectomy, free flap, cephalosporins, clindamycin, опухоли головы и шеи, антибиотикопрофилактика, хирургическая раневая инфекция, чистые раны, условночистые раны, лимфаденэктомия, свободный лоскут, цефалоспорины, клиндамицин

وصف الملف: application/pdf

العلاقة: https://ogsh.abvpress.ru/jour/article/view/527/424Test; Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI:10.3322/caac.21492.; Состояние онкологической помощи населению России в 2017 году. Под ред. В.В. Старинского, А.Д. Каприна, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2018. 236 c. [State of oncological care in Russia in 2017. Ed. by А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: P.A. Hertsen Moscow Oncology Research Center, 2018. 236 p. (In Russ.)].; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7–34. DOI:10.3322/caac.21551.; Gatta G., Botta L., Sánchez M.J. et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: the EUROCARE-5 populationbased study. Eur J Cancer 2015;51(15):2130–43. DOI:10.1016/j.ejca.2015.07.043.; Becker G.D., Parell G.J. Cefazolin prophylaxis in head and neck cancer surgery. Ann Otol Rhinol Laryngol 1979;88(2 Pt 1):183–6. DOI:10.1177/000348947908800206.; Herranz J., Sarandeses A., Fernández M.F. et al. Complications after total laryngectomy in nonradiated laryngeal and hypopharyngeal carcinomas. Otolaryngol Head Neck Surg 2000;122(6):892–8. DOI:10.1016/S0194-59980070020-9.; Crippen M.M., Patel N., Filimonov A. et al. Association of smoking tobacco with complications in head and neck microvascular reconstructive surgery. JAMA Facial Plast Surg 2019;21(1):20–6. DOI:10.1001/jamafacial.2018.1176.; Lahtinen S., Koivunen P., Ala-Kokko T. et al. Quality of life after free flap surgery for cancer of the head and neck in patients with or without postoperative complications. Eur Arch Otorhinolaryngol 2018;275(10):2575–84. DOI:10.1007/s00405-018-5103-4.; Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С. Страчунского, Ю.Б. Белоусова, С.Н. Козлова. Доступно по: http://wwwTest. antibiotic.ru/ab/147-149.shtml. [A practical guide to anti-infectious chemotherapy. Ed. by L.S. Strachunsky, Yu.B. Belousov, S.N. Kozlov. Available at: http://www.antibiotic.ru/ab/147-149.shtmlTest. (In Russ.)].; Ortega G., Rhee D.S., Papandria D.J. et al. An evaluation of surgical site infections by wound classification system using the ACS-NSQIP. J Surg Res 2012;174(1):33–8. DOI:10.1016/j.jss.2011.05.056.; Bratzler D.W., Dellinger E.P., Olsen K.M. et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013;14(1):73–156. DOI:10.1089/sur.2013.9999.; Cruse P.J., Foord R. The epidemiology of wound infection. A 10-year prospective study of 62,939 wounds. Surg Clin North Am 1980;60(1):27–40. DOI:10.1016/s0039-6109(16)42031-1.; Haley R.W., Culver D.H., Morgan W.M. et al. Identifying patients at high risk of surgical wound infection. A simple multivariate index of patient susceptibility and wound contamination. Am J Epidemiol 1985;121(2):206–15. DOI:10.1093/oxfordjournals.aje.a113991.; Olson M., O’Connor M., Schwartz M.L. Surgical wound infections. A 5-year prospective study of 20,193 wounds at the Minneapolis VA Medical Center. Ann Surg 1984;199(3):253–9. DOI:10.1097/00000658-198403000-00001.; Culver D.H., Horan T.C., Gaynes R.P. et al. Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System. Am J Med 1991;91(3B):152S–7S. DOI:10.1016/0002-9343(91)90361-z.; Busch C.-J., Knecht R., Münscher A. et al. Postoperative antibiotic prophylaxis in clean-contaminated head and neck oncologic surgery: a retrospective cohort study. Eur Arch Otorhinolaryngol 2016;273(9):2805–11. DOI:10.1007/s00405-015-3856-6.; Johnson J.T., Yu V.L., Myers E.N., Wagner R.L. An assessment of the need for gram-negative bacterial coverage in antibiotic prophylaxis for oncological head and neck surgery. J Infect Dis 1987;155(2):331–3. DOI:10.1093/infdis/155.2.331.; Murdoch D.A., Telfer M.R., Irvine G.H. Audit of antibiotic policy and wound infection in neck surgery. J R Coll Surg Edinb 1993;38(3):167–9.; Weber R.S., Callender D.L. Antibiotic prophylaxis in clean-contaminated head and neck oncologic surgery. Ann Otol Rhinol Laryngol Suppl 1992;155:16–20. DOI:10.1177/00034894921010S104.; Avenia N., Sanguinetti A., Cirocchi R. et al. Antibiotic prophylaxis in thyroid surgery: a preliminary multicentric Italian experience. Ann Surg Innov Res 2009;3:10. DOI:10.1186/1750-1164-3-10.; Carrau R.L., Byzakis J., Wagner R.L., Johnson J.T. Role of prophylactic antibiotics in uncontaminated neck dissections. Arch Otolaryngol Head Neck Surg 1991;117(2):194–5. DOI:10.1001/archotol.1991.01870140082011.; Man L.-X., Beswick D.M., Johnson J.T. Antibiotic prophylaxis in uncontaminated neck dissection. Laryngoscope 2011;121(7):1473–7. DOI:10.1002/lary.21815.; Coskun H., Erisen L., Basut O. Factors affecting wound infection rates in head and neck surgery. Otolaryngol Head Neck Surg 2000;123(3):328–33. DOI:10.1067/mhn.2000.105253.; Seven H., Sayin I., Turgut S. Antibiotic prophylaxis in clean neck dissections. J Laryngol Otol 2004;118(3):213–6. DOI:10.1258/002221504322927991.; Ketcham A.S., Bloch J.H., Crawford D.T. et al. The role of prophylactic antibiotic therapy in control of staphylococcal infections following cancer surgery. Surg Gynecol Obstet 1962;114:345–52.; Dor P., Klastersky J. Prophylactic antibiotics in oral, pharyngeal and laryngeal surgery for cancer: (a double-blind study). Laryngoscope 1973;83(12):1992–8. DOI:10.1288/00005537-197312000-00009.; Saginur R., Odell P.F., Poliquin J.F. Antibiotic Prophylaxis in head and neck cancer surgery. J Otolaryngol 1988;17(2):78-80.; Sepehr A., Gutierrez Santos B.-J., Chou C. et al. Antibiotics in head and neck surgery in the setting of malnutrition, tracheotomy, and diabetes. Laryngoscope 2009;119(3):549–53. DOI:10.1002/lary.20078.; Langerman A., Thisted R., Hohmann S., Howell M. Antibiotic and duration of perioperative prophylaxis predicts surgical site infection in head and neck surgery. Otolaryngol Head Neck Surg 2016;154(6):1054–63. DOI:10.1177/0194599816634303.; Simo R., French G. The use of prophylactic antibiotics in head and neck oncological surgery. Curr Opin Otolaryngol Head Neck Surg 2006;14(2):55–61. DOI:10.1097/01.moo.0000193183.30687.d5.; Vila P.M., Zenga J., Jackson R.S. Antibiotic prophylaxis in cleancontaminated head and neck surgery: a systematic review and meta-analysis. Otolaryngol Head Neck Surg 2017;157(4):580–8. DOI:10.1177/0194599817712215.; Программа СКАТ (Стратегия Контроля Антимикробной Терапии) при оказании стационарной медицинской помощи. Российские клинические рекомендации. М., 2018. Доступно по: http://nasci.ru/?id=2880Test. [SATC (Strategy of Antimicrobial Therapy Control). Moscow, 2018. Available at: http://nasci.ru/?id=2880Test. (In Russ.)].; Профилактика инфекций области хирургического вмешательства. Клинические рекомендации. Н. Новгород: Ремедиум Приволжье, 2018. Доступно по: http://nasci.ru/?id=2260Test. [Prevention of Infections in the Area of Surgical Intervention. Nizhny Novgorod: Remedium Povolzh’e, 2018. Available at: http://nasci.ru/?id=2260Test. (In Russ.)].; Berríos-Torres S.I., Umscheid C.A., Bratzler D.W. et al. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg 2017;152(8):784–91. DOI:10.1001/jamasurg.2017.0904.; Fee W.E. Jr, Glenn M., Handen C., Hopp M.L. One day vs. two days of prophylactic antibiotics in patients undergoing major head and neck surgery. Laryngoscope 1984;94(5 Pt 1):612–4.; Johnson J.T., Schuller D.E., Silver F. et al. Antibiotic prophylaxis in high-risk head and neck surgery: one-day vs. five-day therapy. Otolaryngol Head Neck Surg 1986;95(5):554–7. DOI:10.1177/019459988609500506.; Bhathena H.M., Kavarana N.M. Prophylactic antibiotics administration head and neck cancer surgery with major flap reconstruction: 1-day cefoperazone versus 5-day cefotaxime. Acta Chir Plast 1998;40(2):36–40.; Liu S.A., Tung K.-C., Shiao J.-Y., Chiu Y.-T. Preliminary report of associated factors in wound infection after major head and neck neoplasm operations – does the duration of prophylactic antibiotic matter? J Laryngol Otol 2008;122(4):403–8. DOI:10.1017/S0022215107007529.; Righi M., Manfredi R., Farneti G. et al. Clindamycin/cefonicid in head and neck oncologic surgery: one-day prophylaxis is as effective as a three-day schedule. J Chemother 1995;7(3):216–20. DOI:10.1179/joc.1995.7.3.216.; Villanueva J.M., Araya I.C., Yanine N.M. Short-term antibiotic prophylaxis versus long-term antibiotic prophylaxis in major clean-contaminated maxillofacial surgery. Rev Chilena Infectol 2012;29(1):14–8. DOI:10.4067/s0716-10182012000100002.; Haidar Y.M., Tripathi P.B., Tjoa T. et al. Antibiotic prophylaxis in cleancontaminated head and neck cases with microvascular free flap reconstruction: a systematic review and meta-analysis. Head Neck 2018;40(2):417–27. DOI:10.1002/hed.24988.; https://ogsh.abvpress.ru/jour/article/view/527Test

الإتاحة: https://doi.org/10.17650/2222-1468-2020-10-2-54-60Test
https://doi.org/10.17650/2222-1468-2020-10-2Test
https://doi.org/10.3322/caac.21492Test
https://doi.org/10.3322/caac.21551Test
https://doi.org/10.1016/j.ejca.2015.07.043Test
https://doi.org/10.1177/000348947908800206Test
https://doi.org/10.1016/S0194-59980070020-9Test
https://doi.org/10.1001/jamafacial.2018.1176Test
https://doi.org/10.1007/s00405-018-5103-4Test
https://doi.org/10.1016/j.jss.2011.05.056Test

المؤلفون: E. Vasil’eva B., A. Vazhenin V., T. Geliashvili M., N. Fadeeva V., A. Garev V., A. Guz’ O., Е. Васильева Б., А. Важенин В., Т. Гелиашвили М., Н. Фадеева В., А. Гарев В., А. Гузь О.

المصدر: Head and Neck Tumors (HNT); Том 8, № 1 (2018); 24-27 ; Опухоли головы и шеи; Том 8, № 1 (2018); 24-27 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2018-8-1

مصطلحات موضوعية: differentiated thyroid cancer, radioiodine therapy, sorafenib, дифференцированный рак щитовидной железы, радиойодтерапия, сорафениб

وصف الملف: application/pdf

العلاقة: https://ogsh.abvpress.ru/jour/article/view/320/310Test; Исаев П.А., Румянцев П.О., Полькин В.В. и др. Клинические случаи эффективности Нексавара (сорафениба) после терапии 131-I у больных метастатическим дифференцированным раком щитовидной железы. Опухоли головы и шеи 2014;(2):46–50. [Isaev P.A., Rumyantsev P.O., Polkin V.V. et al. Clinical expe rience of Nexavar (sorafenib) application in patients with metastatic differentiated thyroid cancer resistant to therapy 131-I. Opukholi golovy i shei = Head and Neck Tumors 2014;(2):46–50. (In Russ.)].; Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9. DOI:10.1210/jc.2005-1322.; Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28. DOI:10.1016/ S0140-6736(14)60421-9.; Гелиашвили Т.М., Важенин А.В., Васильева Е.Б. Опыт работы отделения радионуклидной терапии в ГБУЗ «Челябинский областной клинический онкологический диспансер». В сб.: Онкология – XXI век: материалы XXI Международной научной конфе; ренции по онкологии. Тбилиси, 2017. С. 60–63. [Geliashvili T.M., Vazhenin A.V., Vasil’eva E.B. Work experience of the Department of Radionuclide Therapy at the State Budgetary Healthcare Institution Chelyabinsk Regional Clinical Oncologic Dispensary. In: Oncology – XXI century: Processing of the XXI International Oncology Scientific Conference. Tbilisi, 2017. Pр. 60–63. (In Russ.)].; Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8. DOI:10.1016/S22138587(13)70215-8.; https://ogsh.abvpress.ru/jour/article/view/320Test

الإتاحة: https://doi.org/10.17650/2222-1468-2018-8-1-24-27Test
https://doi.org/10.17650/2222-1468-2018-8-1Test
https://doi.org/10.1210/jc.2005-1322Test
https://doi.org/10.1016/S22138587Test(13)70215-8
https://ogsh.abvpress.ru/jour/article/view/320Test

المؤلفون: T. Sharabura M., A. Vazhenin V., A. Guz O., A. Zakharov S., A. Lozhkov A., O. Davydova N., M. Pimenova M., М. Zbitskaya А., Т. Шарабура М., А. Важенин В., А. Гузь О., А. Захаров С., А. Ложков А., О. Давыдова Н., М. Пименова М., М. Збицкая А.

المصدر: Siberian journal of oncology; Том 16, № 2 (2017); 5-12 ; Сибирский онкологический журнал; Том 16, № 2 (2017); 5-12 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2017-16-2

مصطلحات موضوعية: squamous cell carcinoma of the head and neck, postoperative radiotherapy, local control, risk factors for relapse, reccurences, плоскоклеточный рак головы и шеи, послеоперационная лучевая терапия, локо-регионарный контроль, факторы риска рецидива

وصف الملف: application/pdf

العلاقة: https://www.siboncoj.ru/jour/article/view/513/420Test; Soo K.C., Tan E.H., Wee J., Lim D., Tai B.C., Khoo M.L., Goh C., Leong S.S., Tan T., Fong K.W., Lu P., See A., Machin D. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer. 2005 Aug 8; 93 (3): 279–86.; Tupchong L., Scott C.B., Blitzer P.H., Marcial V.A., Lowry L.D., Jacobs J.R., Stetz J., Davis L.W., Snow J.B., Chandler R. Randomized study of preoperative versus postoperative radiation therapy in advancedhead and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Radiat Oncol Biol Phys. 1991 Jan; 20 (1): 21–8.; Kao J., Lavaf A., Teng M.S., Huang D., Genden E.M. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage. Int J Radiat Oncol Biol Phys. 2008 Jun 1; 71 (2): 362–70. doi:10.1016/j.ijrobp.2007.09.058; Kao J., Lavaf A., Teng M.S., Huang D., Genden E.M. Adjuvant radiotherapy improves overall survival for patients with lymph nodepositive head and neck squamous cell carcinoma. Cancer. 2008 Feb 1; 112 (3): 535–43.; Cooper J.S., Zhang Q., Pajak T.F., Forastiere A.A., Jacobs J., Saxman S.B., Kish J.A., Kim H.E., Cmelak A.J., Rotman M., Lustig R., Ensley J.F., Thorstad W., Schultz C.J., Yom S.S., Ang K.K. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec 1; 84 (5): 1198–205. doi:10.1016/j.ijrobp.2012.05.008.; Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefèbvre J.L., Greiner R.H., Cognetti F. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350 (19): 1945–1952.; Lu H.J., Yang C.C., Wang L.W., Chu P.Y., Tai S.K., Chen M.H., Chang P.M.H. Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer. Biomed Res Int. 2015; 2015: 307576.; Peters L.J., Goepfert H., Ang K.K., Byers R.M., Maor M.H., Guillamondegui O., Oswald M.J. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993; Apr 30; 26 (1): 3–11.; Cooper J.S., Zhang Q., Pajak T.F., Forastiere A.A., Jacobs J., Saxman S.B., Lustig R. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec 1; 84 (5): 1198–205. doi:10.1016/j.ijrobp.2012.05.008.; Studer G., Zwahlen R.A., Graetz K.W., Davis B.J., Glanzmann C. IMRT in oral cavity cancer. Radiation Oncology. 2007; 2: 16.; Eisbruch A., Marsh L.H., Dawson L.A., Bradford C.R., Teknos T.N., Chepeha D.B., Wolf G.T. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 2004; 59 (1): 28–42.; Yao M., Dornfeld K.J., Buatti J.M., Skwarchuk M., Tan H., Nguyen T., Graham S.M. Intensity-modulated radiation treatment for headand-neck squamous cell carcinoma – the University of Iowa experience. Int J Radiat Oncol Biol Phys 2005; 63 (2): 410–421.; Chan A.K., Huang S.H., Le L.W., Yu E., Dawson L.A., Kim J.J., Chan K. Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure. Oral Oncol. 2013 Mar; 49 (3): 255–60. doi:10.1016/j.oraloncology.2012.09.006.; Hsieh C.H., Shueng P.W., Wang L.Y., Liao L.J., Lin Y.C., Kuo Y.S., Hsieh Y.P. Clinical effectiveness, toxicity, and failure patterns of helical tomotherapy for postoperative oral cavity cancer patients. Onco Targets Ther. 2014 Mar 10; 7: 405–14. doi:10.2147/OTT.S59998.eCollection2014.; Chen W.C., Hwang T.Z., Wang W.H., Lu C.H., Chen C.C., Chen C.M., Chen M.F. Comparison between conventional and intensity-modulated post-operative radiotherapy for stage III and IV oral cavity cancer in terms of treatment results and toxicity. Oral Oncol. 2009; 45 (6): 505–10. doi:10.1016/j.oraloncology.2008.07.002.; Lee N., Xia P., Fischbein N.J., Akazawa P., Akazawa C., Quivey J.M. Intensity-modulated radiation therapy for head-and-neck cancer: The UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys. 2003; 57(1): 49–60.; Carrillo M.M., Martín I.T., Lara I.M., de Almodóvar Rivera J.M.R., Ávila R.D.M. Selective use of postoperative neck radiotherapy in oral cavity and oropharynx cancer: a prospective clinical study. Radiat Oncol. 2013; 8: 103. doi:10.1186/1748-717X-8-103.; https://www.siboncoj.ru/jour/article/view/513Test

الإتاحة: https://doi.org/10.21294/1814-4861-2017-16-2-5-12Test
https://doi.org/10.21294/1814-4861-2017-16-2Test
https://doi.org/10.1016/j.ijrobp.2007.09.058Test
https://doi.org/10.1016/j.ijrobp.2012.05.008Test
https://doi.org/10.1016/j.oraloncology.2012.09.006Test
https://doi.org/10.2147/OTT.S59998.eCollection2014Test
https://doi.org/10.1016/j.oraloncology.2008.07.002Test
https://doi.org/10.1186/1748-717X-8-103Test
https://www.siboncoj.ru/jour/article/view/513Test

المؤلفون: A. Guz O., A. Zakharov S., A. Garev V., А. Гузь О., А. Захаров С., А. Гарев В.

المصدر: Siberian journal of oncology; Том 16, № 3 (2017); 104-107 ; Сибирский онкологический журнал; Том 16, № 3 (2017); 104-107 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2017-16-3

مصطلحات موضوعية: implantation metastasis, laryngeal cancer, percutaneous endoscopic gastrostomy, имплантационный метастаз, рак гортани, чрескожная эндоскопическая гастростома

وصف الملف: application/pdf

العلاقة: https://www.siboncoj.ru/jour/article/view/548/449Test; Каприн Д.А., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М. 2017; 250.; Какурина Г.В., Кондакова И.В., Чойнзонов Е.Л., Шишкин Д.А., Черемисина О.В. Особенности протеомы сыворотки крови больных плоскоклеточными карциномами головы и шеи. Сибирский онкологический журнал. 2013; 2: 62–66.; McRackan T.R., Watkins J.M., Herri A.E. Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 2008; 118: 1180–1185.; Preyer S., Thul P. Gastric metastasis of squamous cell carcinoma of the head and neck after percutaneous endoscopic gastrostomy – report of a case. Endoscopy. 1989; 21 (6): 295.; Cappell M.S. Risk factors and risk reduction of malignant seeding of the percutaneous endoscopic gastrostomy track from pharyngoesophageal malignancy: a review of all 44 known reported cases. Am J Gastroenterol. 2007; 102: 1307–1311.; Huang A.T., Georgolios A., Espino S., Kaplan B., Neifeld J., Rei-ter E.R. Percutaneous endoscopic gastrostomy site metastasis from head and neck squamous cell carcinoma: case series and literature review. J Otolaryngol Head Neck Surg. 2013; 42: 20. doi:10.1186/1916-0216-42-20.; https://www.siboncoj.ru/jour/article/view/548Test

الإتاحة: https://doi.org/10.21294/1814-4861-2017-16-3-104-107Test
https://doi.org/10.21294/1814-4861-2017-16-3Test
https://doi.org/10.1186/1916-0216-42-20Test
https://www.siboncoj.ru/jour/article/view/548Test

المؤلفون: A. Guz’ O., A. Zakharov S., A. Garev V., А. Гузь О., А. Захаров С., А. Гарев В.

المصدر: Head and Neck Tumors (HNT); Том 7, № 2 (2017); 92-98 ; Опухоли головы и шеи; Том 7, № 2 (2017); 92-98 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2017-7-2

مصطلحات موضوعية: laryngeal cancer, risk factors, peristomal recurrence, laryngectomy, lymphadenectomy, рак гортани, факторы риска, перистомальный рецидив, ларингэтомия, лимфаденэктомия

وصف الملف: application/pdf

العلاقة: https://ogsh.abvpress.ru/jour/article/view/270/275Test; Petrovic Z., Djordjevic V. Stomal recurrence after primary total laryngectomy. Clin Otolaryngol Allied Sci 2004;29(3):270–3. DOI:10.1111/j.1365–2273.2004.00802.x. PMID: 15142074.; Heron D.E., Rwigema J.C., Gibson M.K. et al. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. A J Clin Oncol 2011;34(2):165–72. DOI:10.1097/COC.0b013e3181dbb73e. PMID: 2068640.; Sher D.J., Haddad R.I., Norris C.M. et al. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer 2010;116 (20):4761–8. DOI:10.1002/cncr.25305. PMID: 20572036.; Spencer S.A., Harris J., Wheeler R.H. et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008;30 (3):281–8. DOI:10.1002/hed.20697. PMID: 17764087.; Keim W.F., Shapiro M.J., Rosin H.D. Study of postlaryngectomy stomal recurrence. Arch Otolaryngol 1965;81(2) 183–6. DOI:10.1001/archotol.1965.00750050190014. PMID: 14233935.; Weisman R.A., Colman M., Ward P.H. Stomal recurrence following laryngectomy a critical evaluation. Ann Otol Rhinol Laryngol 1979;88(6):855–60. DOI:10.1177/000348947908800621.; Yotakis J., Davris S., Kontozoglou T., Adamopoulos G. Evaluation of risk factors for stomal recurrence after total laryngectomy. Clin Otolaryngol Allied Sci 1996;21(2):135–8. DOI:10.1111/j.1365–2273.1996.tb01317.x. PMID: 8735398.; Sartini A.L., Fava A.S., de Faria P.H. Surgical stoma recurrence after total laryngectomy. Braz J Otorhinolaryngol 2007;73(1):80–6. DOI:10.1590/S0034–72992007000100014. PMID: 17505604.; Kowalski L.P. Recidivas de carcinomas da laringe e da parte laringea da faringe na area do traqueostoma-analise dos fatores de risco e do tratamanto. São Paulo: Universidade Federal de São Paulo, 1986. Available at: http://repositorio.unifesp.br/handle/11600/14739Test.; Deeb R., Syamal M., Stachler R. et al. Late Stomal Recurrence 17 Years Post Total Laryngectomy; Case report and Review of Literature. Laryngoscope. 2009;119 (3):238. Available at: http://www.triomeetingposters.org/wp-content/uploads/2009/05/028.pdfTest DOI:10.1002/lary.21496.; Sisson G.A., Bytell D.E., Edison B.D., Yeh S.Jr. Transsternal radical neck dissection for control of stomal recurrences – end results. Laryngoscope. 1975;85(9):1504–10. DOI:10.1288/00005537-197509000-00012. PMID: 1177642.; Sisson G.A. Ogura memorial lecture: mediastinal dissection. Laryngoscope. 1989;99 (12):1262–6. DOI:10.1288/00005537-198912000-00010. PMID: 2601540.; Kowalski L.P., Rinaldo A., Robbins K.T. et al. Stomal recurrence: pathophysiology, treatment and prevention. Acta Otolaryngol 2003;123(3):421–32. DOI:10.1080/00016480310000683a. PMID: 12737302.; Myers E.M., Ogura J.H. Stomal recurrences: a clinicopathological analysis and protocol for future management. Laryngoscope1979;89(7):1121–8. PMID: 449554.; Goodale A., Casper K. Evaluation of risk factors of stomal recurrence following total laryngectomy in laryngeal cancer patients. Available at: http://www.triomeetingposters.org/wp-content/uploads/2012/12/2Test–187. pdf.; De Santi P.R.W. The Lymphatics of the larynx and their relation to malignant disease of that organ. Lancet 1904; 4216 (163):1710–3. Available at: http://www.thelancet.com/journals/lancet/article/PIIS0140Test–6736(01)76391-X/abstract. DOI:10.1016/S0140–6736(01)76391-X.; Guide to TNM Staging of Head and Neck Cancer and Neck Dissection Classification. Eds.: D.G. Deschler, T. Day. 2th ed. Alexandria (VA, USA): American Academy of Otolaryngology – Head and Neck Surgery Foundation, 2008;1:10–23.; Rouvière H. Anatomie des lymphatiques de l’homme. Paris: Masson, 1932.; Chiesa F., Tradati N., Calabrese L. et al. Surgical treatment of laryngeal carcinoma with subglottis involvement. Oncol Rep 2001;8 (1):137–40. DOI:10.3892/or.8.1.137. PMID: 11115585.; Zbären P., Greiner R., Kengelbacher M. Stoma recurrence after laryngectomy: an analysis of risk factors. Otolaryngol Head Neck Surg 1996;114(4):569–75. DOI:10.1016/S0194-59989670248-6 PMID: 8643266.; Weber R.S., Marvel J., Smith P. et al. Paratracheal lymph node dissection for carcinoma of the larynx, hypopharynx, and cervical esophagus. Otolaryngol Head Neck Surg 1993;108(1):11–7. DOI:10.1177/019459989310800102. PMID: 8437869.; Debain J.J., Siardet J., Andrieu-Guitrancourt J. Peritracheal recurrences after total laryngectomy. [Article in French] Ann Otolaryngol Chir Cervicofac 1965;82:382–4. PMID: 5830261.; Breneman J.C., Bradshaw A., Gluckman J., Aron B.S. Prevention of stomal recurrence in patients requiring emergency tracheostomy for advanced laryngeal and pharyngeal tumors. Cancer 1988;62(4):802–5. DOI:10.1002/1097–0142(19880815)62:43.0.CO;2-J. PMID: 3395961.; Reddy S.P., Narayana A., Melian E. at all. Stomal recurrence in patients with Tl glottic cancer after salvage laryngectomy for radiotherapy failures: role of p53 overexpression and subglottic extension. Am J Clin Oncol 2001; 24(2):124–7. PMID: 11319283; Bignardi L., Gavioli C., Staffieri A. Tracheostomal recurrences after laryngectomy. Arch Otorhinolaryngol 1983;238(2):107–13. DOI:10.1007/BF00454301. PMID: 6626023.; De Jong P.C. Intubation and tumour implantation in laryngeal carcinoma. Pract Otorhinolaryngol. 1969;31:119–21.; Condon H.A. Postlaryngectomy stomal recurrence: the influence of endotracheal anaesthesia. British J Anaesth. 1969;41(6):531–533. DOI:10.1093/bja/41.6.531. PMID: 5792886.; Esteban F., Moreno J.A., Delgado-Rodriguez M., Mochon A. Risk factors involved in stomal recurrence following laryngectomy. J Laryngol Otol 1993;107 (6):527–31. DOI:10.1017/S0022215100123618. PMID: 8345300.; León X., Quer M., Burgués J. et al. Prevention of stomal recurrence. Head & Neck 1996;18(1):54–9. DOI:10.1002/(SICI)1097–0347(199601/02)18:13.0. CO;2-Y. PMID: 8774922.; https://ogsh.abvpress.ru/jour/article/view/270Test

الإتاحة: https://doi.org/10.17650/2222-1468-2017-7-2-92-98Test
https://doi.org/10.17650/2222-1468-2017-7-2Test
https://doi.org/10.1111/j.1365Test–2273.2004.00802.x
https://doi.org/10.1097/COC.0b013e3181dbb73eTest
https://doi.org/10.1002/cncr.25305Test
https://doi.org/10.1002/hed.20697Test
https://doi.org/10.1001/archotol.1965.00750050190014Test
https://doi.org/10.1177/000348947908800621Test
https://doi.org/10.1111/j.1365Test–2273.1996.tb01317.x
https://doi.org/10.1590/S0034Test–72992007000100014